Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps

Pinckaers Hans; Wählby Carolina; Mulliqi Nita; Lindberg Johan; Egevad Lars; Litjens Geert; Ji Xiaoyi; Eklund Martin; Ruusuvuori Pekka; Olsson Henrik; Tsuzuki Toyonori; Kartasalo Kimmo; Chen Po-Hsuan Cameron; Bulten Wouter; Samaratunga Hemamali; Rantalainen Mattias; Delahunt Brett

Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps

Pinckaers Hans
Wählby Carolina
Mulliqi Nita
Lindberg Johan
Egevad Lars
Litjens Geert
Ji Xiaoyi
Eklund Martin
Ruusuvuori Pekka
Olsson Henrik
Tsuzuki Toyonori
Kartasalo Kimmo
Chen Po-Hsuan Cameron
Bulten Wouter
Samaratunga Hemamali
Rantalainen Mattias
Delahunt Brett
Katso/Avaa
Publisher's version (615.5Kb)
Lataukset: 

doi:10.1016/j.euf.2021.07.002
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021102752717
Tiivistelmä

Diagnosis and Gleason grading of prostate cancer in biopsies are critical for the clinical management of men with prostate cancer. Despite this, the high grading variability among pathologists leads to the potential for under- and overtreatment. Artificial intelligence (AI) systems have shown promise in assisting pathologists to perform Gleason grading, which could help address this problem. In this mini-review, we highlight studies reporting on the development of AI systems for cancer detection and Gleason grading, and discuss the progress needed for widespread clinical implementation, as well as anticipated future developments.

Patient summary
This mini-review summarizes the evidence relating to the validation of artificial intelligence (AI)-assisted cancer detection and Gleason grading of prostate cancer in biopsies, and highlights the remaining steps required prior to its widespread clinical implementation. We found that, although there is strong evidence to show that AI is able to perform Gleason grading on par with experienced uropathologists, more work is needed to ensure the accuracy of results from AI systems in diverse settings across different patient populations, digitization platforms, and pathology laboratories.

Kokoelmat
  • Rinnakkaistallenteet [19207]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste